Welcome to our dedicated page for Aethlon Medical SEC filings (Ticker: AEMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aethlon Medical, Inc. filings document the regulatory record of a Nevada clinical-stage medical device company developing the investigational Aethlon Hemopurifier. Form 8-K reports cover quarterly financial results furnished under Regulation FD, material agreements tied to securities purchase arrangements, warrant-related capital-structure updates, and approved changes to the company's equity incentive plan.
Proxy materials cover annual-meeting and stockholder voting matters, including governance and compensation-plan proposals. Registration statements describe securities offered for sale, share-capital terms and related offering mechanics for the company's common stock and other securities.
Aethlon Medical, Inc. reports that it remains a clinical-stage company focused on its Hemopurifier device for oncology and life‑threatening viral infections, but continues to generate no revenue and incurs ongoing losses. R&D spending was about $1.91 million in fiscal 2026 and $2.21 million in 2025.
The company had approximately $5.5 million in cash and cash equivalents as of March 31, 2026, and its financial statements carry a going‑concern qualification due to substantial doubt about funding operations 12 months beyond the filing date. It expects to seek additional capital, including through equity financings.
Subsequent to year‑end, Aethlon sold 800,111 shares under its at‑the‑market program for gross proceeds of about $1.90 million, with net proceeds of roughly $1.85 million. As of June 8, 2026, 2,370,560 common shares were outstanding, and remaining capacity under the ATM facility was approximately $542,716.
Aethlon Medical, Inc. reported fiscal year 2026 results showing a substantially narrower loss while advancing its Hemopurifier program. Net loss attributable to common stockholders was $7.2 million for the year ended March 31, 2026, compared with $13.4 million a year earlier as operating expenses fell 21.9% to about $7.3 million.
Other income was $142,000 versus other expense of $4.0 million in the prior year, which had included significant non-cash financing charges. Cash and cash equivalents were about $5.0 million at March 31, 2026, and the company subsequently raised roughly $1.85 million in net proceeds through its at-the-market program.
Clinically, Aethlon advanced its Australian oncology trial into the third and final dosing cohort after independent safety review, treated the first Cohort 3 participant, and continued preclinical work in rheumatoid arthritis and chronic kidney disease. It also obtained new U.S. and European patents for Hemopurifier applications in COVID-19 and Long COVID, extending certain protections into the 2040s.
Aethlon Medical, Inc. updated its at-the-market equity program, allowing sales of common stock with an aggregate offering price of up to $542,716 under its existing agreement with H.C. Wainwright & Co. pursuant to an amended prospectus supplement.
This new capacity follows prior sales of common stock totaling $1,849,457 under the same prospectus. As of June 1, 2026, Aethlon had 2,344,886 shares of common stock outstanding, including 2,337,629 shares held by non-affiliates used to calculate its public float under Form S-3 rules.
AEMD amends its ATM prospectus supplement to update the remaining capacity under its Form S-3 at-the-market program. The amendment states an available aggregate offering price of $542,716 to be sold from time to time through H.C. Wainwright & Co. under the sales agreement. The company reports a public float of $7,176,521 based on 2,337,629 shares held by non-affiliates at a highest closing price of $3.07 per share as of May 27, 2026, and notes prior ATM sales of $1,849,457 during the prior 12 months. Sales are governed by General Instruction I.B.6 of Form S-3 and may be made as at-the-market offerings on Nasdaq or through other permitted methods under the sales agreement.
Aethlon Medical, Inc. reports that Armistice Capital, LLC and Steven Boyd jointly disclose ownership of 82,410 shares of Common Stock, representing 4.99% of the class. The filing states Armistice Capital exercises shared voting and dispositive power over those 82,410 shares under an Investment Management Agreement. The joint Schedule 13G/A is signed by Steven Boyd on 05/15/2026.
Rossetti Angela reported acquisition or exercise transactions in this Form 4 filing.
Aethlon Medical director Angela Rossetti received an equity award of 21,815 shares of Common Stock at $2.29 per share. The award is structured as RSUs that vest in four equal quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026, and March 31, 2027, contingent on her continued service. Following this grant, she directly owns 26,207 shares.
Shah Chetan reported acquisition or exercise transactions in this Form 4 filing.
Aethlon Medical director Chetan Shah received a stock-based compensation grant. He was awarded 21,815 shares of Common Stock at a reference price of $2.29 per share, classified as a grant or award, increasing his directly held stake to 23,021 shares.
The award represents RSUs that vest in four equal quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027, conditioned on his continued service with the company on each vesting date. This is a routine compensation-related equity grant rather than an open-market purchase.
BROENNIMAN EDWARD G reported acquisition or exercise transactions in this Form 4 filing.
Aethlon Medical Inc director Edward G. Broenniman reported an equity award of 21,815 shares of Common Stock at $2.29 per share. The award is in the form of RSUs that vest in four equal quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026, and March 31, 2027, subject to his continued service with the company on each vesting date. Following this grant, he directly holds 23,454 shares of Aethlon Medical common stock.
Aethlon Medical Inc. director Nicolas Gikakis received a stock-based compensation award in the form of 21,815 shares of common stock on April 17, 2026. The award is structured as restricted stock units that vest in four equal quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027, conditioned on his continued service with the company. Following this grant, he directly holds 22,844 shares of Aethlon Medical common stock. This filing reflects a compensation-related acquisition rather than an open-market purchase.
Aethlon Medical director Chetan Shah reported a tax-related share forfeiture tied to equity compensation. On conversion of 268 vested restricted stock units into common stock, he forfeited 178 shares at $2.19 per share to cover tax withholdings, based on the market price at the time.
Following this non-market transaction, Shah directly holds 1,463 shares of Aethlon Medical common stock. The disposition reflects routine tax settlement rather than an open-market sale or purchase decision.